<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112733</url>
  </required_header>
  <id_info>
    <org_study_id>83045809-604.01.02</org_study_id>
    <secondary_id>TAB-2017-22506</secondary_id>
    <nct_id>NCT03112733</nct_id>
  </id_info>
  <brief_title>Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers</brief_title>
  <official_title>Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ilker Kahramanoglu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted
      frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear
      factor (NF)-κB as potential diagnostic and prognostic biomarkers in ovarian carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in discrimination of benign and malignant gynecologic disease</measure>
    <time_frame>2 days</time_frame>
    <description>To measure serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB between groups and to identify a possible significant diagnostic marker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in predicting overall survival and disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To determine any relationship between prognosis of ovarian cancer and serum levels of four different biomarkers</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients with ovarian carcinoma</arm_group_label>
    <description>Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign adnexal mass</arm_group_label>
    <description>Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TFF3, SFRP4, Romo1, NFKB</intervention_name>
    <description>Blood samples of all participants will be collected.</description>
    <arm_group_label>Patients with ovarian carcinoma</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ovarian carcinoma who will be operated in Cerrahpasa Medical Faculty,
        Division of Gynecologic Oncology will participate into the study. Additionally, women
        without any malignancy will participate as control group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of epithelial ovarian carcinoma.

        Exclusion Criteria:

          -  Patients with recurrence.

          -  Patients who received neoadjuvant chemotherapy or radiotherapy

          -  Presence of any secondary malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilker Kahramanoglu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Macit Arvas</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fuat Demirkiran</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tugan Bese</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Turan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hafize Uzun</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Giovanni Vitale</last_name>
    <role>Study Director</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilker Kahramanoglu</last_name>
    <phone>+905334746497</phone>
    <email>ilkerkahramanoglu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasan Turan</last_name>
    <phone>+905056779352</phone>
    <email>hasanturan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilker Kahramanoglu</last_name>
      <phone>+905334746497</phone>
      <email>ilkerkahramanoglu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Lee SH, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, In KH. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer. Lung Cancer. 2014 Aug;85(2):175-81. doi: 10.1016/j.lungcan.2014.05.023. Epub 2014 Jun 5.</citation>
    <PMID>24951318</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu C, Zeng XH, Wang L, Tao SQ, Wu QX, Zhu P, Deng GH, Wang YM. sFRP-4, a potential novel serum marker for chronic hepatitis B-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015 Apr;14(2):164-70.</citation>
    <PMID>25865689</PMID>
  </results_reference>
  <results_reference>
    <citation>Nunes JJ, Pandey SK, Yadav A, Goel S, Ateeq B. Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. Neoplasia. 2017 Apr;19(4):333-345. doi: 10.1016/j.neo.2017.02.002. Epub 2017 Mar 19.</citation>
    <PMID>28319807</PMID>
  </results_reference>
  <results_reference>
    <citation>Edfeldt K, Daskalakis K, Bäcklin C, Norlén O, Tiensuu Janson E, Westin G, Hellman P, Stålberg P. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors. Neuroendocrinology. 2017;105(2):170-181. doi: 10.1159/000452891. Epub 2016 Nov 9.</citation>
    <PMID>27829249</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Ilker Kahramanoglu</investigator_full_name>
    <investigator_title>MD, Gynecologic Oncology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data may be shared with researchers planning to perform a metaanalysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

